Hsieh Louise Tzung-Harn, Nastase Madalina-Viviana, Roedig Heiko, Zeng-Brouwers Jinyang, Poluzzi Chiara, Schwalm Stephanie, Fork Christian, Tredup Claudia, Brandes Ralf P, Wygrecka Malgorzata, Huwiler Andrea, Pfeilschifter Josef, Schaefer Liliana
Pharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe Universität, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany.
National Institute for Chemical-Pharmaceutical Research and Development, 112 Vitan Avenue, Bucharest 031299, Romania.
Int J Mol Sci. 2017 Mar 9;18(3):595. doi: 10.3390/ijms18030595.
In its soluble form, the extracellular matrix proteoglycan biglycan triggers the synthesis of the macrophage chemoattractants, chemokine (C-C motif) ligand CCL2 and CCL5 through selective utilization of Toll-like receptors (TLRs) and their adaptor molecules. However, the respective downstream signaling events resulting in biglycan-induced CCL2 and CCL5 production have not yet been defined. Here, we show that biglycan stimulates the production and activation of sphingosine kinase 1 (SphK1) in a TLR4- and Toll/interleukin (IL)-1R domain-containing adaptor inducing interferon (IFN)-β (TRIF)-dependent manner in murine primary macrophages. We provide genetic and pharmacological proof that SphK1 is a crucial downstream mediator of biglycan-triggered CCL2 and CCL5 mRNA and protein expression. This is selectively driven by biglycan/SphK1-dependent phosphorylation of the nuclear factor NF-κB p65 subunit, extracellular signal-regulated kinase (Erk)1/2 and p38 mitogen-activated protein kinases. Importantly, in vivo overexpression of soluble biglycan causes Sphk1-dependent enhancement of renal CCL2 and CCL5 and macrophage recruitment into the kidney. Our findings describe the crosstalk between biglycan- and SphK1-driven extracellular matrix- and lipid-signaling. Thus, SphK1 may represent a new target for therapeutic intervention in biglycan-evoked inflammatory conditions.
细胞外基质蛋白聚糖双糖链蛋白聚糖以可溶形式通过选择性利用Toll样受体(TLR)及其衔接分子触发巨噬细胞趋化因子、趋化因子(C-C基序)配体CCL2和CCL5的合成。然而,导致双糖链蛋白聚糖诱导CCL2和CCL5产生的各自下游信号事件尚未明确。在此,我们表明双糖链蛋白聚糖以依赖Toll样受体4(TLR4)和含Toll/白细胞介素(IL)-1受体结构域的衔接蛋白诱导干扰素(IFN)-β(TRIF)的方式刺激小鼠原代巨噬细胞中鞘氨醇激酶1(SphK1)的产生和激活。我们提供了遗传学和药理学证据,证明SphK1是双糖链蛋白聚糖触发的CCL2和CCL5 mRNA及蛋白表达的关键下游介质。这是由双糖链蛋白聚糖/SphK1依赖的核因子NF-κB p65亚基、细胞外信号调节激酶(Erk)1/2和p38丝裂原活化蛋白激酶的磷酸化选择性驱动的。重要的是,可溶性双糖链蛋白聚糖的体内过表达导致肾CCL2和CCL5的SphK1依赖性增强以及巨噬细胞向肾脏募集。我们的研究结果描述了双糖链蛋白聚糖和SphK1驱动的细胞外基质和脂质信号之间的相互作用。因此,SphK1可能代表双糖链蛋白聚糖诱发的炎症性疾病治疗干预的新靶点。